Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Shanghai Pharma in Second Round Bidding for $1.5 Billion Cardinal China Deal

publication date: Oct 9, 2017

Shanghai Pharma and FountainVest Partners, a China private equity fund, have submitted second-round bids for Cardinal China's drug distribution operations. According to a Bloomberg article, the two entities are part of a smaller group of still-interested bidders that also includes Warburg Pincus of the US and PAG Asia Capital, a China/Asia investor. Cardinal China's operations are expected to draw bids in the $1-$1.5 billion range, though Cardinal may keep its China operations if it doesn't receive a suitable bid. More details....

Stock Symbols: (SHA: 601607) (NYSE: CAH)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital